BMC pharmacology & toxicology · 2026
Clinical efficacy analysis of secukinumab combined with calcipotriol cream in the treatment of moderate to severe psoriasis in elderly patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Ling, Li Wei, Li Qian, Gao Xinjing, Zeng Jingxin, Zhou Xin, Liu Weiyu, Zhong Xuelian, Yang Yunqing, Zhang Xibao, Luo Quan
Аннотация
BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory skin disorder, with plaque psoriasis being the most common clinical subtype, especially in elderly patients. Conventional therapies often provide suboptimal outcomes, necessitating the exploration of novel treatment approaches. This study evaluates the clinical efficacy of combining Secukinumab with Calcipotriol Cream in elderly patients with moderate to severe psoriasis.
METHODS: A total of 160 elderly patients (≥ 65 years) with plaque psoriasis were retrospectively analyzed between January 2020 and December 2024. All patients received baseline therapy with oral acitretin and topical clobetasol. The observation group (n = 80) additionally received secukinumab and calcipotriol cream. The control group (n = 80) received baseline therapy only. The primary endpoint was overall clinical efficacy based on Psoriasis Area and Severity Index (PASI) improvement. Secondary endpoints included changes in PASI scores, Dermatology Life Quality Index (DLQI), skin barrier parameters (stratum corneum hydration and sebum content), and incidence of adverse events over 12 weeks.
RESULTS: The total efficacy rate was significantly higher in the observation group than in the control group (90.0% vs. 72.5%, χ² = 8.306, P = 0.040). PASI scores were significantly reduced in both groups, with a greater reduction observed in the observation group (16.12 ± 3.13 vs. 18.98 ± 3.92; P < 0.001). Improvements in stratum corneum hydration (54.08 ± 6.05 vs. 50.20 ± 5.74; P < 0.001) and sebum content (138.20 ± 12.39 vs. 129.72 ± 10.68; P < 0.001) were also greater in the observation group. DLQI scores improved more significantly in the observation group (7.82 ± 1.05 vs. 9.52 ± 1.38; P < 0.001). Adverse events were infrequent and comparable between groups (P = 0.168). Post hoc power analysis confirmed sufficient statistical power (> 80%) across all primary endpoints.
CONCLUSIONS: This retrospective study suggests that secukinumab combined with calcipotriol cream improves clinical outcomes and quality of life with good tolerability in elderly patients with moderate to severe psoriasis, supporting its potential therapeutic utility.
CLINICAL TRIAL: Not applicable.
METHODS: A total of 160 elderly patients (≥ 65 years) with plaque psoriasis were retrospectively analyzed between January 2020 and December 2024. All patients received baseline therapy with oral acitretin and topical clobetasol. The observation group (n = 80) additionally received secukinumab and calcipotriol cream. The control group (n = 80) received baseline therapy only. The primary endpoint was overall clinical efficacy based on Psoriasis Area and Severity Index (PASI) improvement. Secondary endpoints included changes in PASI scores, Dermatology Life Quality Index (DLQI), skin barrier parameters (stratum corneum hydration and sebum content), and incidence of adverse events over 12 weeks.
RESULTS: The total efficacy rate was significantly higher in the observation group than in the control group (90.0% vs. 72.5%, χ² = 8.306, P = 0.040). PASI scores were significantly reduced in both groups, with a greater reduction observed in the observation group (16.12 ± 3.13 vs. 18.98 ± 3.92; P < 0.001). Improvements in stratum corneum hydration (54.08 ± 6.05 vs. 50.20 ± 5.74; P < 0.001) and sebum content (138.20 ± 12.39 vs. 129.72 ± 10.68; P < 0.001) were also greater in the observation group. DLQI scores improved more significantly in the observation group (7.82 ± 1.05 vs. 9.52 ± 1.38; P < 0.001). Adverse events were infrequent and comparable between groups (P = 0.168). Post hoc power analysis confirmed sufficient statistical power (> 80%) across all primary endpoints.
CONCLUSIONS: This retrospective study suggests that secukinumab combined with calcipotriol cream improves clinical outcomes and quality of life with good tolerability in elderly patients with moderate to severe psoriasis, supporting its potential therapeutic utility.
CLINICAL TRIAL: Not applicable.